Lazard acted as the exclusive financial advisor to Paratek Pharmaceuticals, and Skadden, Arps, Slate, Meagher & Flom LLP ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Regeneron Pharmaceuticals announced Monday it plans to purchase human genetics and biotechnology firm 23andMe from bankruptcy ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’s Ratings downgraded the sovereign credit ...

Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies ...